Visus CEO updates on lead product candidate, 2021 pipeline

Visus Therapeutics CEO Ben Bergo shares an update on the status of its lead product candidate for presbyopia treatment as well as what's in the company's pipeline for 2021.


See more AAO coverage here

Related Content:

ConferencesRefractivePharmacy
What the impact of 44-week aflibercept data may mean in a real-world setting
VIEW 1 and VIEW 2 studies: taking a deeper dive
Study: Children with vision impairment more likely to suffer from depression and anxiety